Cytokinetics Inc (CYTK): Mark Lampert’s Biotechnology Value Fund Loads Up On More Shares

Page 8 of 14 SEC Filing

1	NAME OF REPORTING PERSON Mark N. Lampert
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) x   (b) o
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0 shares
	6	SHARED VOTING POWER 3,908,329 (1)
	7	SOLE DISPOSITIVE POWER 0 shares
	8	SHARED DISPOSITIVE POWER 3,908,329 (1)
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,908,329 (1)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.1% (1)
12	TYPE OF REPORTING PERSON   IN

(1)  Excludes 921,052 shares of Common Stock issuable upon the exercise of certain Warrants (defined below). The Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, more than 9.98% of the number of shares of Common Stock then issued and outstanding.

Follow Cytokinetics Inc (NASDAQ:CYTK)

Follow Cytokinetics Inc (NASDAQ:CYTK)

---

or

Subscribe with Google

We may use your email to send marketing emails about our services. Click here to read our privacy policy.